Gofen & Glossberg’s Definium Therapeutics DFTX Stock Holding History

Gofen & Glossberg’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,833	Closed	-$46K	–	583
2022 Q2	$46K	Hold	4,833	–	–	﹤0.01%	543
2022 Q1	$80K	Hold	4,833	–	–	﹤0.01%	583
2021 Q4	$100K	Hold	4,833	–	–	﹤0.01%	589
2021 Q3	$169K	Hold	4,833	–	–	﹤0.01%	564
2021 Q2	$250K	Buy	+4,833	New	+$254K	0.01%	482

Other funds holding DFTX

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Gofen & Glossberg's DFTX Position: Q3 2022 in Review

Gofen & Glossberg sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 4,833 shares — an estimated $46K sold.

Gofen & Glossberg first reported a position in DFTX in Q2 2021 and held it in 5 quarters. The position peaked at $250K in Q2 2021. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

Gofen & Glossberg reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
Gofen & Glossberg sold 4,833 Definium Therapeutics shares in Q3 2022, an estimated $46K.
Gofen & Glossberg first reported a position in Definium Therapeutics in Q2 2021 and held it in 5 quarters.
Gofen & Glossberg's Definium Therapeutics position peaked at $250K in Q2 2021.
101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Gofen & Glossberg's 13F filing for Q3 2022, filed 13 Oct 2022.